In the present study, CD5+ DLBCL showed female predominance, higher IPI and Ann Arbor stages, and other aggressive clinical features, which are in line with previous reports [1, 5, 7–9, 13, 14, 20, 21, 23]. This evidence concerns the gene CD5 and diffuse large B-cell lymphoma.